Physician profile
Asad Sheikh
NPI 1760573356
$13,866.34
in general payments reported to CMS, 2019-2025
36 companies · $9,016 in 2025
The $9,016 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $426 · 2021: $564 · 2023: $1,060 · 2024: $2,249 · 2025: $9,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,273 · Food and Beverage: $5,352 · Travel and Lodging: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,272.50 |
| Food and Beverage | $5,352.05 |
| Travel and Lodging | $700.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,683.32 | 2020-2025 | Rybrevant, Carvykti, Erleada |
| Geron Corporation | $3,315.86 | 2025 | Imetelstat |
| Daiichi Sankyo INC. | $1,123.24 | 2019-2025 | Enhertu, Enhertu, Vanflyta |
| Sobi, INC | $427.32 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $375.42 | 2023-2024 | Reblozyl, Pomalyst, Opdivo |
| Novartis Pharmaceuticals Corporation | $350.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $327.18 | 2024-2025 | Ojjaara |
| Astrazeneca Pharmaceuticals Lp | $322.63 | 2024-2025 | Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $277.51 | 2024-2025 | Fruzaqla, Alunbrig |
| Celgene Corporation | $254.44 | 2021-2024 | Reblozyl |
| Lilly USA, LLC | $234.70 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Dendreon Pharmaceuticals LLC | $225.25 | 2024-2025 | Provenge |
| Agios Pharmaceuticals, INC. | $143.44 | 2025 | Pyrukynd |
| Puma Biotechnology, INC. | $140.68 | 2023-2025 | |
| Beigene USA, INC. | $138.70 | 2024-2025 | Brukinsa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $130.00 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $129.65 | 2025 | |
| Seagen INC. | $124.99 | 2020 | |
| Genzyme Corporation | $123.58 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $120.43 | 2023-2024 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $119.02 | 2021-2025 | Phesgo, Columvi, Kadcyla |
| Rigel Pharmaceuticals, INC. | $117.93 | 2023 | Rezlidhia, Tavalisse |
| Astellas Pharma US INC | $114.28 | 2020 | |
| Merck Sharp & Dohme LLC | $89.13 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $88.90 | 2019 | |
| Caris Mpi, INC. | $60.00 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $58.11 | 2024 | Sylvant |
| Array Biopharma INC | $39.95 | 2024 | Braftovi, Lorbrena, Mektovi |
| Sumitomo Pharma America, INC. | $36.94 | 2024 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $33.17 | 2025 | Libtayo |
| Novocure INC. | $32.51 | 2023 | |
| Karyopharm Therapeutics INC. | $26.85 | 2025 | Xpovio |
| Gilead Sciences, INC. | $23.97 | 2024 | |
| Mirati Therapeutics, INC. | $21.56 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $18.70 | 2024 | |
| Adc Therapeutics America, INC. | $16.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.